The Committee discusses Amgen’s supplemental New Drug Application (sNDA) 214665/S-005, for LUMAKRAS (sotorasib) tablets for proposed treatment of adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer. This supplement proposes to convert the NDA to full approval based on the confirmatory study, CodeBreaK 200. The virtual meeting will be held on October 5 at 9:30 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMGN:
- BCBSM modifying weight loss drug coverage to require ‘lifestyle modifications’
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call
- Amgen price target raised to $280 from $260 at Argus
- Amgen presents new LUMAKRAS plus chemotherapy data in first-line KRAS G12C NSCLC
- Meet Bullfrog AI: Fly exclusive interview with CEO Vin Singh